ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
Dow Jones
38,852.27
0.46%
US Dollar vs MXN
16.8828
-0.59%
Brent Oil
83.475
0.42%
Bitcoin
63,179.58
-1.28%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) Noticias

EVAX Evaxion Biotech AS

3.91
-0.04 (-1.01%)
Fuera de horario
Última actualización: 15:00:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Evaxion Biotech AS EVAX NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.04 -1.01% 3.91 15:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.99 3.79 4.16 3.91 3.95
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202416:01EDGAR2Form F-1 - Registration statement for certain foreign..
17/4/202407:00GLOBEEvaxion Announces Phase 2 Clinical Trial Update: First..
02/4/202406:00GLOBEEvaxion and Undisclosed Collaborator Announce Encouraging..
27/3/202406:30GLOBEEvaxion Announces Business Update and Full Year 2023..
19/3/202406:30GLOBEEvaxion Hosts R&D Day and Unveils the Broad Potential of Its..
29/2/202406:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202406:30GLOBEEvaxion to Host R&D Day on March 19, 2024, Highlighting its..
20/2/202406:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202406:30GLOBEEvaxion Announces Successful Completion of the Initial..
07/2/202415:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202407:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202407:30GLOBEEvaxion Regains Compliance with Nasdaq Minimum Bid Price..
06/2/202407:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/2/202407:30GLOBEEvaxion Announces Closing of $15 Million Public Offering
05/2/202408:09EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/2/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
01/2/202408:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202408:20GLOBEEvaxion Biotech Announces Pricing of $15 Million Public..
31/1/202416:10EDGAR2Form F-1/A - Registration statement for certain foreign..
31/1/202408:26EDGAR2Form F-1/A - Registration statement for certain foreign..
30/1/202414:16EDGAR2Form F-1/A - Registration statement for certain foreign..
26/1/202415:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202413:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202407:30GLOBEEvaxion to Develop Tailored Novel Cancer Vaccines Based upon..
22/1/202415:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202415:30GLOBEEvaxion Announces Completion of ADS Ratio Change
12/1/202416:17EDGAR2Form F-1 - Registration statement for certain foreign..
12/1/202408:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/1/202407:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:30GLOBEEvaxion Announces Plan to Implement ADS Ratio Change
21/12/202315:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202315:30GLOBEEvaxion Biotech Announces Closing of Private Placement
19/12/202315:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202315:15GLOBEEvaxion Announces Business Update and Third Quarter 2023..
19/12/202308:25GLOBEEvaxion Biotech Announces Private Placement Financing
19/12/202307:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/12/202315:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202307:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202307:27GLOBEEvaxion to Unveil Potentially Groundbreaking AI-Immunology™..
17/11/202308:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202307:00GLOBEEvaxion Presents Proof-of-Principle for Its Unique AI Model..
06/11/202309:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202309:12GLOBEEvaxion Shares Latest EVX-01 Phase 2 Clinical Data in..
31/10/202310:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202310:14GLOBEEvaxion Announces Encouraging Initial Phase 2 Clinical Data..
26/10/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/10/202307:30GLOBENew and Exciting Clinical Data on Evaxion’s..

Su Consulta Reciente

NASDAQ
EVAX
Evaxion Biotech AS
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados